GOV.UK
Medicines and Healthcare products Regulatory Agency
Regulatory Agency
- Drug and device alerts
- Drug Safety Update
- Yellow Card: Report a problem with a medicine or medical device
- Blood regulation and safety
- Marketing authorisations and licensing guidance
- Patient information leaflets and summaries of product characteristics
- Drug Analysis Prints (DAPs)
- Public assessment reports
- Medical devices regulation and safety
- Contact MHRA
- All MHRA services and information
Featured
Collection
MHRA guidance and publications on a possible no deal scenario
Information about the regulation of medicines and medical devices if the UK leaves the EU with no deal.
News story
Expert Advisory Group set-up to review paclitaxel drug-coated balloon catheters and drug-eluting stents
The Expert Advisory Group will review Paclitaxel drug-coated balloon catheters and drug-eluting stents which are used to treat patients with peripheral arterial disease.
Press release
Opioid Expert Working Group meets at MHRA
An Expert Working Group (EWG) of the UK’s Commission on Human Medicines (CHM) met yesterday at the Medicines and Healthcare products Regulatory Agency (MHRA) to begin the review of the benefits and risks of opioid medicines, including dependence and addiction.
Press release
Medicine mailing man sentenced for illicit supply
Today at Aylesbury Crown Court Keith Morgan of Milton Keynes was sentenced for illegally selling or supplying prescription-only medicine and unauthorised medicine.
Press release
Three further batches of blood pressure and heart medication recalled from pharmacies
MHRA has recalled 3 batches of Losartan tablets due to contamination with the nitrosamine N-nitroso-N-methylamino butyric acid.
Decision
Suspended and revoked licences and registrations for manufacturers and wholesalers of medicines and ingredients
Public list of companies in the UK who have had their licence/registration to manufacture or wholesale medicines/ingredients revoked or suspended.
Latest from the Medicines and Healthcare products Regulatory Agency
- EAMS Scientific Opinion: polatuzumab vedotin in combination with bendamustine and rituximab for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in adult patients who are not eligible for hematopoietic stem cell transplant
- Advertising investigations: May 2019
- Clinical trials for medicines: apply for authorisation in the UK
Subscriptions
Subscribe to feed
What the Medicines and Healthcare products Regulatory Agency does
The Medicines and Healthcare products Regulatory Agency regulates medicines, medical devices and blood components for transfusion in the UK.
MHRA is an executive agency, sponsored by the Department of Health and Social Care.
Follow us
Documents
Services
See all servicesNews and communications
See all news and communicationsOur management
Contact MHRA
General enquiries
10 South Colonnade
London
E14 4PU
United Kingdom
Telephone
020 3080 6000
Fax
020 3118 9803
Office hours are Monday to Friday, 9am to 5pm.
Media enquiries
MHRA
10 South Colonnade
London
E14 4PU
United Kingdom
During office hours:
020 3080 7651 (08:30 - 17:00)
Out of office hours:
07770 446 189 (17:00 - 08:30)
Office hours are Monday to Friday, 8:30am to 5pm. For real-time updates including the latest press releases and news statements, see our Twitter channel at https://www.twitter.com/mhrapress
Make an FOI request
- Read about the Freedom of Information (FOI) Act and how to make a request.
- Check our previous releases to see if we’ve already answered your question.
- Make a new request by contacting us using the details below.
Freedom of Information
Corporate information
Jobs and contracts